10-Q: Aquestive Therapeutics Reports First Quarter 2024 Results, Bolstered by Public Offering and Pipeline Progress

Sentiment:

Quarterly Report 7 May 2024 4:23 PM

📋All filings for Aquestive Therapeutics, INC

Aquestive Therapeutics' Q1 2024 results show increased revenue and a significant cash boost from a public offering, alongside advancements in their drug pipeline.

Capital raiseThe company completed an underwritten public offering of common stock, raising net proceeds of $70.5 million.The underwriters exercised an over-allotment option, providing an additional $2.5 million in gross proceeds.The company has an active ATM facility and a purchase agreement with Lincoln Park Capital, providing additional avenues for capital raising.

Worse than expectedThe company reported a net loss of $12.8 million for the quarter, compared to a net income of $8.1 million in the same period last year.

Summary

Aquestive Therapeutics reported a net loss of $12.8 million for the first quarter of 2024, compared to a net income of $8.1 million in the same period last year.
Total revenue for the quarter was $12.1 million, an 8% increase year-over-year, driven by higher manufacturing and supply revenue, and license and royalty revenue.
The company completed an underwritten public offering of common stock, raising net proceeds of $70.5 million, and an additional $2.5 million from an over-allotment option.
Operating expenses increased, with research and development costs rising by 67% to $5.9 million, primarily due to clinical trial costs for Anaphylm.
Selling, general, and administrative expenses also increased by 43% to $10.7 million, due to higher personnel costs, severance, and share-based compensation.
The company's cash and cash equivalents stood at $95.2 million as of March 31, 2024, a significant increase from $23.9 million at the end of 2023.
Aquestive continues to advance its product pipeline, including Anaphylm for anaphylaxis and Libervant for epilepsy, with a goal to file an NDA for Anaphylm before the end of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made significant progress in its clinical programs and has strengthened its financial position through a public offering, it also reported a net loss and faces several risks and challenges. The sentiment is cautiously optimistic.

Positives

The company experienced an 8% increase in total revenue year-over-year.
Aquestive successfully raised significant capital through a public offering, strengthening its financial position.
The company made substantial progress in its clinical programs, particularly with Anaphylm.
The FDA approved Libervant for a specific patient population, marking a significant regulatory milestone.
The company's cash position has improved significantly, providing financial flexibility for future operations.

Negatives

Aquestive reported a net loss of $12.8 million for the quarter, a significant swing from the net income of $8.1 million in the same period last year.
Operating expenses, particularly research and development and selling, general, and administrative costs, increased substantially.
The company is still dependent on external financing to achieve its operating plan.
The company is facing challenges in overcoming the orphan drug market exclusivity for Libervant in patients 12 years and older.
The company is facing ongoing litigation, including product liability lawsuits related to Suboxone.

Risks

The company faces risks associated with the development and regulatory approval of its product candidates, including Anaphylm.
There is a risk of delays or failure to receive FDA approval for Anaphylm and other drug candidates.
The company may not be able to overcome the orphan drug exclusivity for Libervant in the older patient population.
Aquestive is subject to litigation risks, including product liability lawsuits and patent infringement claims.
The company's financial performance is dependent on the success of its product pipeline and its ability to secure additional funding.
The company is facing risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties.

Future Outlook

Aquestive aims to file an NDA for Anaphylm before the end of 2024 and continues to advance its product pipeline, including Libervant for epilepsy. The company expects to incur losses and negative cash flows for the foreseeable future and will be dependent on external financing.

Management Comments

Aquestive is focused on advancing its product pipeline, including Anaphylm and Libervant.
The company is managing business costs to prepare for a potential decline in Suboxone revenue.
Management believes the company's ongoing business, existing cash, and access to capital markets provide near-term liquidity.

Industry Context

Aquestive is operating in the pharmaceutical industry, focusing on innovative drug delivery technologies. The company is competing with other pharmaceutical companies in the development of treatments for anaphylaxis and epilepsy. The company is also facing competition from generic versions of its licensed products.

Comparison to Industry Standards

The increase in R&D spending is typical for a biotech company in the clinical development phase, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
The reliance on external financing is common for companies in the early stages of commercialization, comparable to companies like Inovio Pharmaceuticals and Novavax.
The company's revenue growth is moderate compared to some high-growth biotech companies, but it is consistent with companies that have a mix of commercialized and pipeline products, such as Amarin Corporation.
The company's cash position is strong following the public offering, which is a positive sign compared to companies with limited cash reserves, such as Cassava Sciences.

Legal Proceedings

Aquestive is involved in ongoing patent-related litigation with Teva Pharmaceuticals.
The company is a defendant in a lawsuit filed by Humana in Kentucky.
Aquestive is involved in a lawsuit with Neurelis, Inc. in California.
The company is a defendant in over 350 product liability lawsuits related to Suboxone.

Stakeholder Impact

Shareholders will benefit from the increased cash position and potential for future growth.
Employees may be impacted by changes in staffing levels and compensation.
Customers will benefit from the development of new and improved treatment options.
Suppliers may see increased demand for raw materials and manufacturing services.
Creditors will be impacted by the company's debt obligations and financial performance.

Next Steps

Aquestive plans to continue clinical development of Anaphylm, including a temperature/pH study, a self-administration study, and an allergen exposure study.
The company plans to commence a pediatric study for Anaphylm in the second half of 2024.
A pre-NDA meeting with the FDA for Anaphylm is targeted for the second half of 2024.
The company aims to file the NDA for Anaphylm before the end of 2024.
Aquestive will continue to commercialize Libervant for patients between two and five years of age.

Key Dates

Date	Description
2016-04-01	Aquestive entered into a license agreement with Sunovion Pharmaceuticals Inc.
2017-09-24	Aquestive entered into a supplemental agreement with Indivior.
2019-07-15	Aquestive completed a private placement of 12.5% Senior Secured Notes.
2019-09-11	Aquestive established an ATM facility.
2019-12-05	Neurelis Inc. filed a lawsuit against Aquestive Therapeutics, Inc.
2020-11-03	Aquestive entered into a Monetization Agreement with Marathon.
2020-11-20	Aquestive began utilizing the ATM facility.
2021-03-26	Aquestive filed a prospectus supplement to offer additional shares under the ATM.
2022-03-03	Aquestive entered into the Haisco Agreement.
2022-04-12	Aquestive entered into the Lincoln Park Purchase Agreement.
2022-05-17	Keith J. Kendall left Aquestive Therapeutics, Inc.
2022-06-01	Aquestive entered into Securities Purchase Agreements.
2022-09-07	Aquestive filed a prospectus supplement to register the offer and sale of shares of Common Stock.
2022-09-26	Aquestive entered into the Pharmanovia Agreement.
2022-10-26	Aquestive entered into the Assertio Agreement.
2023-03-27	Aquestive amended the Pharmanovia Agreement.
2023-08-01	Aquestive entered into a Letter Agreement with the Exercising Holder of warrants.
2023-11-01	Aquestive issued 13.5% Senior Secured Notes.
2024-03-22	Aquestive completed the Underwritten Public Offering.
2024-04-03	Aquestive filed a prospectus supplement to register the offer and sale of shares of Common Stock.
2024-04-22	Underwriters purchased additional shares to cover over-allotments in the Underwritten Public Offering.
2024-04-23	The 2024 Registration Statement was declared effective by the SEC.
2024-04-26	FDA approved Libervant for patients between two and five years of age.

Keywords

Aquestive Therapeutics, Anaphylm, Libervant, epinephrine, diazepam, pharmaceuticals, clinical trials, FDA approval, public offering, revenue, net loss, research and development, CNS, epilepsy, anaphylaxis

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.